摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-benzyl-4,5,7,8-tetrahydro-6-methoxy-6-methoxycarbonyl-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione | 155568-55-1

中文名称
——
中文别名
——
英文名称
3-benzyl-4,5,7,8-tetrahydro-6-methoxy-6-methoxycarbonyl-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione
英文别名
3-benzyl-4,5,7,8-tetrahydro-6-methoxy-6-methoxycarbonyl-6H-imidazo[4,5-e][1,4]diazepine-5,8-dione;3-Benzyl-4,5,7,8-tetrahydro-6-methoxy-6-methoxycarbonyl-6h-imidazo[4,5-e][1,4]-diazepine-5,8-dione;methyl 3-benzyl-6-methoxy-5,8-dioxo-4,7-dihydroimidazo[4,5-e][1,4]diazepine-6-carboxylate
3-benzyl-4,5,7,8-tetrahydro-6-methoxy-6-methoxycarbonyl-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione化学式
CAS
155568-55-1
化学式
C16H16N4O5
mdl
——
分子量
344.327
InChiKey
ZERKUJSUMKRXBY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    112
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-benzyl-4,5,7,8-tetrahydro-6-methoxy-6-methoxycarbonyl-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione盐酸 作用下, 以 甲醇 为溶剂, 反应 0.5h, 以86%的产率得到5-氨基-1-苄基咪唑-4-甲酰胺
    参考文献:
    名称:
    含咪唑并[4,5- e ] [1,4]二氮杂ring环系统的扩环黄嘌呤的反应†
    摘要:
    4,5,7,8-四氢-6 H-咪唑并[4,5- e ] [1,4]二氮杂-5,8-二酮在2-位进行溴化,在3-,4位有或没有取代基-或7位,使用溴,N-溴琥珀酰亚胺或乙酰基次螨。如在7中那样,用酯官能度活化6位并没有改变溴化位点。环打开前体的碱催化的溴化,二乙基2- [ Ñ - (1-苄基-5-硝基咪唑-4-碳基)氨基]丙二酸二乙酯(5),无论是在引入的烷氧基官能度导致高于氨基丙二酸酯侧链,产生17当用醇淬灭反应时,或在侧链降解中,当用水淬灭反应时,产生1-苄基-5-硝基咪唑-4-羧酰胺(19)。17和19两者都是通过5 经由溴中间体15的氧化溴化而形成的。通过5的碱催化甲基化获得了后者的间接证据,得到2-甲基-2- [ N-(1-(1-苄基-5-硝基酰亚胺-偶氮基-4-羰基)氨基]丙二酸二乙酯(21)。用N-溴代琥珀酰亚胺对5进行碱催化的溴化反应生成了两种产物二聚体24a含有取代的2,2
    DOI:
    10.1002/jhet.5570300544
  • 作为产物:
    描述:
    参考文献:
    名称:
    含咪唑并[4,5- e ] [1,4]二氮杂ring环系统的扩环黄嘌呤的反应†
    摘要:
    4,5,7,8-四氢-6 H-咪唑并[4,5- e ] [1,4]二氮杂-5,8-二酮在2-位进行溴化,在3-,4位有或没有取代基-或7位,使用溴,N-溴琥珀酰亚胺或乙酰基次螨。如在7中那样,用酯官能度活化6位并没有改变溴化位点。环打开前体的碱催化的溴化,二乙基2- [ Ñ - (1-苄基-5-硝基咪唑-4-碳基)氨基]丙二酸二乙酯(5),无论是在引入的烷氧基官能度导致高于氨基丙二酸酯侧链,产生17当用醇淬灭反应时,或在侧链降解中,当用水淬灭反应时,产生1-苄基-5-硝基咪唑-4-羧酰胺(19)。17和19两者都是通过5 经由溴中间体15的氧化溴化而形成的。通过5的碱催化甲基化获得了后者的间接证据,得到2-甲基-2- [ N-(1-(1-苄基-5-硝基酰亚胺-偶氮基-4-羰基)氨基]丙二酸二乙酯(21)。用N-溴代琥珀酰亚胺对5进行碱催化的溴化反应生成了两种产物二聚体24a含有取代的2,2
    DOI:
    10.1002/jhet.5570300544
点击查看最新优质反应信息

文献信息

  • Novel inhibitors of guanase
    作者:Anila Bhan、Ramachandra S. Hosmane
    DOI:10.1016/0040-4039(94)85016-x
    日期:1994.9
    Synthesis and guanase inhibitory activity of two novel 5:7-fused heterocycles, 15 and 16, containing the imidazo[4,5-e][1,4]diazepine ring system, have been reported.
    据报道,含有咪唑并[4,5- e ] [1,4]二氮杂ring环系统的两个新颖的5:7稠合杂环15和16的合成及其对鸟苷酸的抑制活性。
  • Analogues of Azepinomycin: Inhibitors of Guanase
    作者:Anila Bhan、Ramachandra Hosmane
    DOI:10.1080/15257779508012405
    日期:1995.5.1
    Synthesis and guanase Inhibitory activity of two novel 5:7-fused heterocyles, 15 and 16, containing the imidazo[4,5-e][1,4]diazepine ring system, have been reported.
  • A Unique Diaminomalonate Derivatve useful for Building Novel Heterocycles
    作者:Anila Bhan、Ramachandra S. Hosmane、Hongming Zhang、Narayan S. Hosmane
    DOI:10.1080/00397919508011820
    日期:1995.9
    The synthetic utility of a unique diaminomalonate derivative (1) for constructing novel heterocycles, e.g. 5, has been demonstrated.
  • Design of inhibitors against guanase: Synthesis and biochemical evaluation of analogues of azepinomycin
    作者:Ravi K. Ujjinamatada、Anila Bhan、Ramachandra S. Hosmane
    DOI:10.1016/j.bmcl.2006.08.033
    日期:2006.11
    As part of a program to design rational, mechanism-based inhibitors of guanase, we report here the synthesis and biochemical screening of two analogues of azepinomycin (1 and 2), a naturally occurring inhibitor of guanase, known to mimic the transition-state of the enzyme-catalyzed reaction. Our biochemical results show that compounds 1 and 2 are competitive inhibitors with K-i of 2.01 +/- 0.16 x 10(-5) and 5.36 +/- 0.14 x 10(-5) M, respectively. (c) 2006 Elsevier Ltd. All rights reserved.
  • Reactions of ring-expanded xanthines containing the imidazo[4,5-<i>e</i>][1,4]diazepine ring system
    作者:Anila Bhan、Ramachandra S. Hosmane
    DOI:10.1002/jhet.5570300544
    日期:1993.10
    corresponding amino derivative 25, followed by ring-closure with sodium meth-oxide/methanol, yielded three products, a 5:6-fused system 26 and two 5:7 fused systems 27 and 28. The structures of 26 and 27 were confirmed by single-crystal X-ray diffraction analyses. A tentative reaction pathway for the formation of all three products has been proposed. Hydrolysis of 27 with aqueous hydrochloric acid resulted in
    4,5,7,8-四氢-6 H-咪唑并[4,5- e ] [1,4]二氮杂-5,8-二酮在2-位进行溴化,在3-,4位有或没有取代基-或7位,使用溴,N-溴琥珀酰亚胺或乙酰基次螨。如在7中那样,用酯官能度活化6位并没有改变溴化位点。环打开前体的碱催化的溴化,二乙基2- [ Ñ - (1-苄基-5-硝基咪唑-4-碳基)氨基]丙二酸二乙酯(5),无论是在引入的烷氧基官能度导致高于氨基丙二酸酯侧链,产生17当用醇淬灭反应时,或在侧链降解中,当用水淬灭反应时,产生1-苄基-5-硝基咪唑-4-羧酰胺(19)。17和19两者都是通过5 经由溴中间体15的氧化溴化而形成的。通过5的碱催化甲基化获得了后者的间接证据,得到2-甲基-2- [ N-(1-(1-苄基-5-硝基酰亚胺-偶氮基-4-羰基)氨基]丙二酸二乙酯(21)。用N-溴代琥珀酰亚胺对5进行碱催化的溴化反应生成了两种产物二聚体24a含有取代的2,2
查看更多

同类化合物

脱氧助间型霉素 化合物RK-33 8-叔-丁基1-乙基6,7-二氢-5H-咪唑并[1,5-A][1,4]二氮杂卓-1,8(9H)-二甲酸基酯 8-(叔丁氧羰基)-6,7,8,9-四氢-5H-咪唑并[1,5-A][1,4]二氮杂-1-羧酸 6-羟基-4,5,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-8(1H)-酮 5-(8-羟基-7,8-二氢-4H-咪唑并[5,4-d][1,3]二氮杂卓-3-基)-3-(羟基甲基)环戊-3-烯-1,2-二醇 4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮 3-[(2-羟基乙氧基)甲基]-3,4,7,8-四氢咪唑并[4,5-d][1,3]二氮杂卓-8-醇 1H-咪唑并[1,5-d〕〔1,4]二氮杂(9CI) 1,4,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-5,8-二酮 (9ci)-1H-咪唑并[1,2-a][1,4]二氮杂卓 5-methylthio-11H-imidazo[1,2-c][1,3]benzodiazepine 2-methoxy-1,4,7-trimethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-5,7-diphenyl-4,5,7,8-tetrahydroimidazo<4,5-e><1,3>diazepin-6-one 6-amino-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione [3-(2-Deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8 tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol]-5'-phosphoric Acid-(3-dodecylmercapto-2-decyloxy)-propyl Ester (4S)-4-benzyl-2-(2,5-dihydroxyphenyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one (4S)-4-benzyl-2-(2,5-dimethoxyphenyl)-3,4-dihydro-5H-pyrido[10,20:1,2]imidazo [4,5-d][1,3]diazepin-5-one (4S)-4-methyl-2-(1-naphthyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one 6-amino-1-(2'-deoxy-β-D-erythropentofuranosyl)-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione 6-amino-1-(2'-deoxy-α-D-erythropentofuranosyl)-4,5-dihydro-8H-imidazo[4,5-e][1,3]diazepine-4,8-dione (4S)-4-methyl-2-(4-acetamidophenyl)-3,4-dihydro-5H-pyrido[1',2':1,2]imidazo-[4,5-d][1,3]diazepin-5-one 5-(4-methyl-1-piperazinyl)-11H-imidazo[1,2-c][1,3]benzodiazepine monomaleate (8R)-3-[(4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol (R)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol 6-(decylamino)-1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7H-imidazo[4,5-e][1,3]diazepine-4,8-dione (13S)-11-(4-methoxyphenyl)-13-methyl-2,8,10,12-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7,11-pentaen-14-one (8R)-3-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol 8-Ketodeoxycoformycin 2'-chloropentostatin CO-Vidarabine (8R)-3-[(1S,2R,4R)-2-(benzoyloxymethyl)-1-benzoyloxycyclopent-4-yl]-8-[(tert-butyldimethylsilyl)oxy]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepine (8R)-3-Benzyl-6-(tert-butoxycarbonyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine (8R)-3-(2'-Cyanoethyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine 4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4-propyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4,7-diethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 1-benzyl-4-isobutyl-7-methyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 4,6-diamino-6-(ethylimino)-1,6-dihydroimidazo[4,5-e][1,3]diazepine 4,5-dihydro-8H-6-(N-hexadecyl)amino-1-(2'-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,5-dihydro-8H-6-(N-tetradecyl)amino-1-(2'-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,5-dihydro-8H-6-(N-octadecyl)amino-1-(2-deoxy-α-D-erythropentofuranosyl)imidazo[4,5-e]diazepine-4,8-dione 4,6-diamino-6-(octadecylimino)-1,6-dihydroimidazo[4,5-e][1,3]diazepine 8-Imino-2,4-dimethyl-7-phenyl-7,8-dihydro-4H-1,2a,4,5,7-pentaaza-cyclopenta[cd]azulene-3,6-dione 1,4-dimethyl-4,5,7,8-tetrahydro-6H-imidazo<4,5-e><1,4>diazepine-5,8-dione 11H-imidazo[1,2-c][1,3]benzodiazepine-5(6H)-thione (8R)-3-[(4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol 2-(4-Chloro-benzylcarbamoyl)-6-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-hexanoic acid benzyl ester (13S)-13-(1H-indol-3-ylmethyl)-2,8,10,12-tetrazatricyclo[7.5.0.02,7]tetradeca-1(9),3,5,7-tetraene-11,14-dione